Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Press releases

Sequana Medical to host a Key Opinion Leader Webinar on “The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”

  Live webinar with Dr. Vargas and Dr. Knuttinen on 15 July 2021 at 4 pm CET  / 10 am ET Ghent, BELGIUM – 17 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart...

Results from Sequana Medical’s RED DESERT alfapump DSR® study selected for presentation at the Heart Failure 2021 Online Congress

Ghent, BELGIUM – 9 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the abstract on the results from its RED DESERT alfapump DSR (Direct Sodium Removal) study has been...

Sequana Medical announces first patient enrolled in SAHARA DESERT

alfapump® DSR study in Heart Failure patients with persistent congestion Ghent, BELGIUM – 1 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the SAHARA DESERT study. Interim...

Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders

PRESS RELEASE REGULATED INFORMATION 27 May 2021, 06:00 pm CEST   Ghent, BELGIUM – 27 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the...

Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 11 May 2021, 07:00 am CEST   RED DESERT data of all patients confirm: alfapump DSR is highly effective at managing fluid and sodium balance in diuretic-resistant heart failure patients without need for loop diuretics restoration of diuretic response and improvement in cardio-renal function improvement in diuretic response...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASE REGULATED INFORMATION 3 May 2021, 07:00 am CEST   Ghent, Belgium, 3 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act...

Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2021

PRESS RELEASE REGULATED INFORMATION 27 April 2021, 07:00 am CEST   Publication of Annual Report 2020 Ghent, Belgium, 27 April 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today invites the holders of...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASE REGULATED INFORMATION 25 March 2021, 06:00 pm CET   Ghent, Belgium, 25 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act...

Sequana Medical announces 2020 Full Year Results and 2021 Outlook

PRESS RELEASE REGULATED INFORMATION 17 March 2021 07:00 CET                 POSEIDON – positive interim results in Q4 2020; additional interim results expected in Q2 2021 and primary endpoint in Q2 2022 RED DESERT – positive interim results in Q4 2020; top-line data expected in Q2 2021 Successful equity placements extend cash runway into Q2...

Sequana Medical Notice of 2020 Full Year Results and Business Update

Ghent, BELGIUM – 10 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live...
1 2 3 4 9

Subscribe to our Press Releases

    I agree to the Sequana Medical Privacy Policy

    We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close